59122-93-9
Chemical Structure
Neoisoliquiritin
Synonym(s): Neoisoliquiritigenin
- CAS. Nr.: 59122-93-9
- Formula:C21H22O9
- Molecular Weight:418.39
IUPAC Name: (E)-1-(2-hydroxy-4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
InChIKey: XQWFHGOIUZFQPJ-LXGDFETPSA-N
SMILES: O=C(C1=CC=C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)C=C1O)/C=C/C3=CC=C(O)C=C3
Biological Activity: Neoisoliquiritin (Neoisoliquiritigenin) is an androgen receptor (AR) inhibitor. Neoisoliquiritin inhibits the ATPase activity of GRP78. Neoisoliquiritin induces G0/G1 cell cycle arrest and inhibits proliferation in cancer cells, while it also induces cell apoptosis (apoptosis). Neoisoliquiritin suppresses tumor growth in mouse models of prostate cancer and breast cancer. Neoisoliquiritin can be used in studies related to prostate cancer and breast cancer[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Neoisoliquiritin | 99.74% | Neoisoliquiritin (Neoisoliquiritigenin) is an androgen receptor (AR) inhibitor. Neoisoliquiritin inhibits the ATPase activity of GRP78. Neoisoliquiritin induces G0/G1 cell cycle arrest and inhibits proliferation in cancer cells, while it also induces cell apoptosis (apoptosis). Neoisoliquiritin suppresses tumor growth in mouse models of prostate cancer and breast cancer. Neoisoliquiritin can be used in studies related to prostate cancer and breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chen C, et al. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2021 May;85:153514. [Content Brief]
- [2]. Tang H, et al. Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer. Current cancer drug targets. 2018;18(4):390-399. [Content Brief]
